Study with dapagliflozin - GLORIA

Study identifier:D1690R00030

ClinicalTrials.gov identifier:NCT02971618

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Observational retrospective multicenter study to evaluate clinical outcome variables change with dapaGLiflozin treatment introduced in patients with T2D uncOntrolled by the current therapy in real clinical practice in RussIA

Medical condition

Diabetes mellitus type 2

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

929

Study type

Observational

Age

18 Years - 65 Years

Date

Study Start Date: 21 Feb 2017
Primary Completion Date: 03 Aug 2018
Study Completion Date: 03 Aug 2018

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria